Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.41 |
| ▸ | LMNA | P02545 | 6/20 | 0.41 |
| ▸ | TP53 | P04637 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 4/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | JUN | P05412 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17059747 | 0.77 | MAPT (0.46) | MAPTLMNATP53POLBPABPC1 | |
| SCHEMBL10098778 | 0.76 | ALDH1A1 (0.58) | MAPTTP53POLBHPGDJUN | |
| SCHEMBL10098691 | 0.74 | MAPK7 (0.56) | — | |
| SCHEMBL24334888 | 0.72 | CASP3 (0.38) | POLBHPGDJUNNFKB1NFKB2 | |
| SCHEMBL14288794 | 0.72 | MAOA (0.64) | MAPTLMNATP53POLBPABPC1 | |
| SCHEMBL23428462 | 0.71 | TNK2 (0.61) | — | |
| SCHEMBL16065742 | 0.71 | MAPK7 (0.45) | HPGDJUNNFKB1NFKB2RELA | |
| SCHEMBL9101431 | 0.70 | LMNA (0.58) | MAPTLMNATP53POLBALDH1A1 | |
| SCHEMBL25357908 | 0.68 | DCLK1 (0.52) | CASP3 | |
| SCHEMBL30526068 | 0.68 | DCLK1 (0.52) | CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3255047-B1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND USES IN TREATING DISORDERS | DANA FARBER CANCER INST INC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-10570154-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| EP-2379559-B1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INST INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170260208-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260208-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9701683-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701683-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160347755-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160347755-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9464091-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464091-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-05 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2010080712-A2 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INSTITUTE (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, BRSK1, TAOK3 | MAPT 1759/4885LMNA 4512/4885TP53 1017/4885 |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | MAPT 1726/4885LMNA 4448/4885TP53 1050/4885 |
| US-10570154-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | BRSK2, STK3, BRSK1 | MAPT 1726/4885LMNA 4448/4885TP53 1050/4885 |
| US-20160347755-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | MAPT 2051/4885LMNA 4371/4885TP53 1204/4885 |
| US-20170260208-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | MAPT 1726/4885LMNA 4448/4885TP53 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.